Showing results (401-410 of 418) with videos related to
Sort By:
Pageof 42
Nature Genetics|February 6, 2007
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genomeNathaniel D Heintzman, Rhona K Stuart, Gary Hon, et al.Molecular Psychiatry|April 15, 2022
Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophreniaSamantha V Abram, Brian J Roach, Susanna L Fryer, et al.The ISME Journal|August 12, 2017
Feathermoss and epiphytic Nostoc cooperate differently: expanding the spectrum of plant-cyanobacteria symbiosisDenis Warshan, Josh L Espinoza, Rhona K Stuart, et al.British Journal of Haematology|November 19, 2014
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemiaRobert K Stuart, Larry D Cripe, Michael B Maris, et al.The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasmsBeata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.Pageof 42